Comorbidities and Costs of Adult Patients Diagnosed with Attention-Deficit Hyperactivity Disorder

Author： Kristina Secnik   Andrine Swensen   Maureen J. Lage  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.1, 2005-01, pp. : 93-102

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Medication Costs to Private Insurers of Diversion of Medications for Attention-Deficit Hyperactivity Disorder

By Aldridge Arnie P.  

PharmacoEconomics, Vol. 29, Iss. 7, 2011-07 ,pp. : 621-635

Adis International

Access to resources Recommend Favorite

Adult Attention Deficit Hyperactivity Disorder

By  

Child and Adolescent Psychopharmacology News, Vol. 9, Iss. 8, 2004-12 ,pp. : 1-7

Guilford Publications Inc

Access to resources Recommend Favorite

Substance Abuse in Patients with Attention-Deficit Hyperactivity Disorder: Therapeutic Implications

By Schubiner Howard  

CNS Drugs, Vol. 19, Iss. 8, 2005-01 ,pp. : 643-655

Adis International

Access to resources Recommend Favorite

Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions

By Dell'Agnello Grazia  

CNS Drugs, Vol. 23, Iss. 9, 2009-09 ,pp. : 739-753

Adis International

Access to resources Recommend Favorite

OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder

By McBurnett Keith   Starr H Lynn  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 2, 2011-02 ,pp. : 315-324

Informa Healthcare

Access to resources Recommend Favorite